{"id":"nivolumab-or-pembrolizumab","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Fatigue"},{"rate":"15–25","effect":"Pruritus"},{"rate":"10–20","effect":"Rash"},{"rate":"10–20","effect":"Diarrhea"},{"rate":"10–15","effect":"Nausea"},{"rate":"3–5","effect":"Immune-related pneumonitis"},{"rate":"2–5","effect":"Immune-related hepatitis"},{"rate":"2–4","effect":"Immune-related colitis"},{"rate":"5–10","effect":"Immune-related thyroiditis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nivolumab and pembrolizumab are monoclonal antibodies that bind to programmed death receptor-1 (PD-1) on T cells, preventing interaction with PD-L1 and PD-L2 ligands on tumor cells. This blockade releases the 'brakes' on the immune system, restoring T-cell proliferation, activation, and anti-tumor function. By reinvigorating exhausted T cells, these drugs enable durable anti-tumor immunity across multiple cancer types.","oneSentence":"These drugs block the PD-1 checkpoint protein on immune cells, allowing the immune system to recognize and attack cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:30.046Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"},{"name":"Non-small cell lung cancer (NSCLC)"},{"name":"Renal cell carcinoma"},{"name":"Hodgkin lymphoma"},{"name":"Head and neck squamous cell carcinoma"},{"name":"Gastric cancer"},{"name":"Colorectal cancer (microsatellite instability-high or mismatch repair-deficient)"}]},"trialDetails":[{"nctId":"NCT03620019","phase":"PHASE2","title":"Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2018-09-10","conditions":"Melanoma Stage Iii, Melanoma Stage Iv, Melanoma","enrollment":25},{"nctId":"NCT03546686","phase":"PHASE2","title":"Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-11-12","conditions":"Breast Cancer","enrollment":51},{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8","enrollment":8300},{"nctId":"NCT04930783","phase":"PHASE1","title":"NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2022-01-03","conditions":"Melanoma, Metastatic Melanoma","enrollment":10},{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT04462406","phase":"PHASE2","title":"Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-09","conditions":"Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":150},{"nctId":"NCT04387084","phase":"PHASE1","title":"Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2020-08-12","conditions":"Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm","enrollment":10},{"nctId":"NCT05700461","phase":"PHASE1","title":"Drug Screening Using Novel IMD in Renal Cell Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"Oliver Jonas","startDate":"2024-12-01","conditions":"Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer","enrollment":20},{"nctId":"NCT04637594","phase":"PHASE3","title":"Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2022-05-27","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma","enrollment":3},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT04902040","phase":"PHASE1, PHASE2","title":"Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-04-14","conditions":"Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm","enrollment":19},{"nctId":"NCT06264180","phase":"PHASE3","title":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-07-11","conditions":"Advanced Melanoma","enrollment":400},{"nctId":"NCT03313804","phase":"PHASE2","title":"Priming Immunotherapy in Advanced Disease With Radiation","status":"COMPLETED","sponsor":"John L. Villano, MD, PhD","startDate":"2017-10-26","conditions":"Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck","enrollment":76},{"nctId":"NCT04697576","phase":"PHASE1","title":"Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma","status":"RECRUITING","sponsor":"Carlo Contreras","startDate":"2021-10-20","conditions":"Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8","enrollment":36},{"nctId":"NCT05733689","phase":"PHASE1","title":"Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-27","conditions":"Gastroesophageal Adenocarcinoma","enrollment":20},{"nctId":"NCT05926960","phase":"PHASE2","title":"A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma","status":"TERMINATED","sponsor":"Pfizer","startDate":"2023-06-13","conditions":"Melanoma","enrollment":38},{"nctId":"NCT06488482","phase":"PHASE3","title":"Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2024-12-19","conditions":"High-risk Melanoma","enrollment":1792},{"nctId":"NCT06561386","phase":"PHASE3","title":"A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2024-10-07","conditions":"Non-small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT06632327","phase":"PHASE3","title":"Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2024-12-11","conditions":"Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":1100},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT07436390","phase":"NA","title":"IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma","status":"COMPLETED","sponsor":"Institute of Oncology Ljubljana","startDate":"2024-03-31","conditions":"Metastatic Melanoma, Malignant Melanoma, Skin Cancer","enrollment":132},{"nctId":"NCT07428252","phase":"NA","title":"Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2022-03-01","conditions":"Metastatic Malignant Melanoma","enrollment":150},{"nctId":"NCT07422779","phase":"NA","title":"Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2022-03-01","conditions":"Metastatic Melanoma, Skin Cancer","enrollment":100},{"nctId":"NCT07419932","phase":"","title":"Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer","status":"RECRUITING","sponsor":"Fujian Medical University","startDate":"2025-12-23","conditions":"Thyroid Cancer, Thyroid Neoplasms","enrollment":120},{"nctId":"NCT07420439","phase":"PHASE2","title":"Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease","status":"NOT_YET_RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2026-05-15","conditions":"Non Small Cell Lung Cancer Metastatic, Interstitial Lung Disease (ILD)","enrollment":108},{"nctId":"NCT04848519","phase":"PHASE2","title":"Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2021-05-20","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma","enrollment":6},{"nctId":"NCT04594187","phase":"PHASE2","title":"Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-08-26","conditions":"Melanoma","enrollment":168},{"nctId":"NCT05487859","phase":"PHASE2","title":"Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2025-12-31","conditions":"Kidney Cancer","enrollment":""},{"nctId":"NCT05987332","phase":"PHASE2, PHASE3","title":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"IDEAYA Biosciences","startDate":"2023-10-31","conditions":"Metastatic Uveal Melanoma","enrollment":420},{"nctId":"NCT03993353","phase":"PHASE2","title":"Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2020-04-07","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma","enrollment":7},{"nctId":"NCT06731270","phase":"PHASE2","title":"Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-04-09","conditions":"Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":20},{"nctId":"NCT05993234","phase":"","title":"A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)","status":"RECRUITING","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2023-12-05","conditions":"HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma","enrollment":257},{"nctId":"NCT04044859","phase":"PHASE1","title":"ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"USWM CT, LLC","startDate":"2019-08-20","conditions":"Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ)","enrollment":120},{"nctId":"NCT05358938","phase":"EARLY_PHASE1","title":"Exercise to Boost Response to Checkpoint Blockade Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-06-21","conditions":"Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma","enrollment":22},{"nctId":"NCT05533697","phase":"PHASE1, PHASE2","title":"Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2022-09-01","conditions":"Advanced Solid Tumors","enrollment":361},{"nctId":"NCT07383441","phase":"PHASE3","title":"Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-06-10","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8","enrollment":718},{"nctId":"NCT06283238","phase":"","title":"Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2025-04-16","conditions":"GastroEsophageal Cancer","enrollment":""},{"nctId":"NCT03356470","phase":"","title":"Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-11-02","conditions":"Melanoma","enrollment":5},{"nctId":"NCT06599619","phase":"","title":"Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi","status":"RECRUITING","sponsor":"John Kirkwood","startDate":"2025-02-20","conditions":"Melanoma","enrollment":30},{"nctId":"NCT04995003","phase":"PHASE1","title":"HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2021-12-07","conditions":"Sarcoma, HER-2 Protein Overexpression, Osteosarcoma","enrollment":25},{"nctId":"NCT05327686","phase":"PHASE2","title":"Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-02-01","conditions":"Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8","enrollment":240},{"nctId":"NCT03228667","phase":"PHASE2","title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-12-11","conditions":"Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma","enrollment":40},{"nctId":"NCT05034536","phase":"PHASE2","title":"PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-02-07","conditions":"Metastatic Melanoma","enrollment":36},{"nctId":"NCT07277777","phase":"PHASE2","title":"125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors","status":"NOT_YET_RECRUITING","sponsor":"Li Min","startDate":"2026-01","conditions":"Malignant Tumors","enrollment":90},{"nctId":"NCT04490564","phase":"","title":"Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma","status":"COMPLETED","sponsor":"Pharmassist Ltd","startDate":"2019-06-25","conditions":"Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma","enrollment":135},{"nctId":"NCT04729322","phase":"PHASE2","title":"Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-22","conditions":"Metastatic Colorectal Adenocarcinoma, Metastatic Small Intestinal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8","enrollment":15},{"nctId":"NCT04079166","phase":"PHASE2","title":"SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Scancell Ltd","startDate":"2019-08-19","conditions":"Malignant Melanoma, Melanoma (Skin), Melanoma Stage III","enrollment":173},{"nctId":"NCT06584435","phase":"PHASE2","title":"A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2022-10-10","conditions":"High-risk Renal Cell Carcinoma","enrollment":100},{"nctId":"NCT06908993","phase":"PHASE3","title":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2025-12-09","conditions":"Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation","enrollment":133},{"nctId":"NCT07256184","phase":"","title":"Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center Analysis","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2022-11-15","conditions":"Metastatic Malignant Melanoma","enrollment":232},{"nctId":"NCT07224971","phase":"PHASE2","title":"Impact of Circadian Rhythm on Immunotherapy","status":"RECRUITING","sponsor":"Liza Villaruz, MD","startDate":"2025-12-02","conditions":"Advanced/Metastatic NSCLC","enrollment":350},{"nctId":"NCT06841679","phase":"PHASE2, PHASE3","title":"Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","startDate":"2025-08-28","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":778},{"nctId":"NCT05901285","phase":"PHASE1","title":"Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Vaxiion Therapeutics","startDate":"2023-11-02","conditions":"Advanced Solid Tumor, Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab","enrollment":43},{"nctId":"NCT07223424","phase":"PHASE2","title":"Patient Preference for Subcutaneous vs. Intravenous Immune Therapy","status":"RECRUITING","sponsor":"Diwakar Davar","startDate":"2025-11-04","conditions":"Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma","enrollment":480},{"nctId":"NCT02955290","phase":"PHASE1, PHASE2","title":"CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2016-12-22","conditions":"Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma","enrollment":51},{"nctId":"NCT06345183","phase":"","title":"Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2024-02-19","conditions":"Advanced Renal Cell Carcinoma (aRCC)","enrollment":327},{"nctId":"NCT03589339","phase":"PHASE1","title":"NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nanobiotix","startDate":"2019-01-16","conditions":"Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour","enrollment":145},{"nctId":"NCT05846646","phase":"PHASE2","title":"Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC","status":"TERMINATED","sponsor":"ImmuneSensor Therapeutics Inc.","startDate":"2023-06-28","conditions":"Oligometastatic Disease","enrollment":6},{"nctId":"NCT03505320","phase":"PHASE2","title":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-06-29","conditions":"Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer","enrollment":143},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT04887870","phase":"PHASE2, PHASE3","title":"Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study","status":"COMPLETED","sponsor":"Mirati Therapeutics Inc.","startDate":"2021-06-29","conditions":"Advanced or Metastatic Solid Malignancies","enrollment":52},{"nctId":"NCT04954599","phase":"PHASE1, PHASE2","title":"Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI","status":"RECRUITING","sponsor":"Maastricht University Medical Center","startDate":"2023-05-30","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":126},{"nctId":"NCT03693014","phase":"PHASE2","title":"A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-10-01","conditions":"Metastatic Cancer, Melanoma Cancer, Lung Cancer","enrollment":69},{"nctId":"NCT04295863","phase":"PHASE1","title":"Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2020-06-25","conditions":"Metastatic Cancer","enrollment":264},{"nctId":"NCT06463665","phase":"PHASE2","title":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2024-09-26","conditions":"Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer","enrollment":142},{"nctId":"NCT07190027","phase":"PHASE1, PHASE2","title":"Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-11","conditions":"Advanced Non-Small Cell Lung Cancer (NSCLC)","enrollment":246},{"nctId":"NCT05838729","phase":"PHASE1, PHASE2","title":"Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer","status":"RECRUITING","sponsor":"Coordination Pharmaceuticals, Inc.","startDate":"2023-04-03","conditions":"Head Neck Cancer, Intratumoral Injection","enrollment":16},{"nctId":"NCT03647163","phase":"PHASE1, PHASE2","title":"Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vyriad, Inc.","startDate":"2019-04-09","conditions":"Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma","enrollment":33},{"nctId":"NCT06840782","phase":"PHASE3","title":"First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09-09","conditions":"Oligometastatic Non-small Cell Lung Cancer (NSCLC)","enrollment":124},{"nctId":"NCT06624644","phase":"PHASE2, PHASE3","title":"A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma","status":"RECRUITING","sponsor":"Linnaeus Therapeutics, Inc.","startDate":"2025-08-06","conditions":"Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma","enrollment":135},{"nctId":"NCT04510597","phase":"PHASE3","title":"Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2021-03-08","conditions":"Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8","enrollment":364},{"nctId":"NCT06771674","phase":"","title":"Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Hookipa Biotech GmbH","startDate":"2024-06-05","conditions":"Oropharyngeal Squamous Cell Carcinoma","enrollment":662},{"nctId":"NCT03409016","phase":"","title":"Biomarkers of Immune-Related Toxicity","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2018-04-18","conditions":"Cancer, Metastatic Cancer","enrollment":69},{"nctId":"NCT07061379","phase":"","title":"Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2025-07-24","conditions":"PROMs","enrollment":144},{"nctId":"NCT07130032","phase":"PHASE2","title":"Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade","status":"RECRUITING","sponsor":"EuroCityClinic LLC","startDate":"2025-08-14","conditions":"Metastatic Non-small Cell Lung Cancer (NSCLC), Metastatic Cutaneous Melanoma","enrollment":90},{"nctId":"NCT07111104","phase":"","title":"Survival Efficacy of Combined Radiotherapy and Immunotherapy in Patients With Metastatic Non-small Cell Lung Carcinoma","status":"COMPLETED","sponsor":"Hopitaux Prives de Metz, Groupe UNEOS","startDate":"2024-10-14","conditions":"Non Small Cell Lung Cancer Metastatic","enrollment":350},{"nctId":"NCT02628574","phase":"PHASE1","title":"Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab","status":"COMPLETED","sponsor":"Leap Therapeutics, Inc.","startDate":"2016-01","conditions":"Solid Tumors","enrollment":109},{"nctId":"NCT03872947","phase":"PHASE1","title":"A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Toray Industries, Inc","startDate":"2019-04-26","conditions":"Solid Tumor, Colorectal Cancer, Cholangiocarcinoma","enrollment":138},{"nctId":"NCT05303493","phase":"PHASE1","title":"Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2022-06-29","conditions":"NSCLC Stage IV, Melanoma Stage IV, Unresectable Melanoma","enrollment":45},{"nctId":"NCT05341349","phase":"PHASE1","title":"Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2022-10-13","conditions":"Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in the Brain","enrollment":1},{"nctId":"NCT05195619","phase":"PHASE1","title":"Personalized DC Vaccines in Non Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2022-03-22","conditions":"Non-small Cell Lung Cancer","enrollment":16},{"nctId":"NCT04581382","phase":"EARLY_PHASE1","title":"Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2020-12-14","conditions":"Melanoma","enrollment":18},{"nctId":"NCT07054086","phase":"","title":"Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-03-01","conditions":"Esophageal Cancer","enrollment":30},{"nctId":"NCT07050524","phase":"PHASE2","title":"Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-09-01","conditions":"Gastric Cancer Stage III","enrollment":80},{"nctId":"NCT06903312","phase":"PHASE4","title":"Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-06-15","conditions":"Renal Cell Cancer, Kidney Neoplasm, Immunotherapy","enrollment":409},{"nctId":"NCT06054152","phase":"","title":"CX3CR1+T Cell Predict Immunotherapy Efficacy","status":"COMPLETED","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2023-04-10","conditions":"Non-small Cell Lung Cancer","enrollment":150},{"nctId":"NCT07036016","phase":"","title":"Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1","status":"COMPLETED","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2015-01-01","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":67818},{"nctId":"NCT07035860","phase":"","title":"Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ji Yongling","startDate":"2025-06-16","conditions":"Carbon Ion Radiotheray","enrollment":34},{"nctId":"NCT03645928","phase":"PHASE2","title":"Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2019-05-07","conditions":"Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer","enrollment":245},{"nctId":"NCT06728657","phase":"PHASE2","title":"Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma","status":"SUSPENDED","sponsor":"Fudan University","startDate":"2024-07-01","conditions":"Stomach Adenocarcinoma, Gastro-esophageal Junction Cancer","enrollment":68},{"nctId":"NCT05180799","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of BA3071 in Patients With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioAtla, Inc.","startDate":"2022-08-03","conditions":"NSCLC, Melanoma","enrollment":320},{"nctId":"NCT06063681","phase":"PHASE1","title":"A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Stingray Therapeutics","startDate":"2023-10-12","conditions":"Advanced / Metastatic Solid Tumor","enrollment":25},{"nctId":"NCT02419495","phase":"PHASE1","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-26","conditions":"Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":221},{"nctId":"NCT07000253","phase":"PHASE2, PHASE3","title":"Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2026-01","conditions":"Esophageal Cancer, Gastric (Stomach) Cancer, Gastric Adenocarcinoma","enrollment":290},{"nctId":"NCT05704985","phase":"PHASE1","title":"Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"DEKA Biosciences","startDate":"2023-04-03","conditions":"Cancer, Solid Tumor, Colorectal Cancer","enrollment":39},{"nctId":"NCT06988592","phase":"","title":"GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-05-23","conditions":"Advanced Biliary Tract Cancer","enrollment":100},{"nctId":"NCT06991907","phase":"NA","title":"PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety","status":"COMPLETED","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2020-01-01","conditions":"HCC - Hepatocellular Carcinoma, 125I Seeds Implantation","enrollment":80},{"nctId":"NCT03432741","phase":"PHASE1","title":"Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2018-03-27","conditions":"Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma","enrollment":17},{"nctId":"NCT04909164","phase":"","title":"The Prospective Non-randomized Case-control Study From Real-world Lung Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2021-06-15","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":1500},{"nctId":"NCT04134325","phase":"EARLY_PHASE1","title":"Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-09-01","conditions":"Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22382,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Immune checkpoint inhibitors","Opdivo and Keytruda"],"phase":"phase_3","status":"active","brandName":"Nivolumab or pembrolizumab","genericName":"Nivolumab or pembrolizumab","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"These drugs block the PD-1 checkpoint protein on immune cells, allowing the immune system to recognize and attack cancer cells. Used for Metastatic melanoma, Non-small cell lung cancer (NSCLC), Renal cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}